Research

Scientific Publications:  

  1. Yosdel Soto, Arletty Hernández, Roger Sarduy, Victor Brito, Sylvie Marleau, Donna F. Vine, Ana M. Vázquez, Spencer D. Proctor.   Monoclonal Antibody chP3R99 Reduces Subendothelial Retention of Atherogenic Lipoproteins in Insulin‐Resistant Rats: Acute Treatment Versus Long‐Term Protection as an Idiotypic Vaccine for Atherosclerosis. Journal of the American Heart Association.  27 June 2024, Volume 13, Number 13.  https://doi.org/10.1161/JAHA.123.032419
  2. Yosdel Soto, Arletty Hernández, Roger Sarduy, Victor Brito, Sylvie Marleau, Donna F. Vine, Ana M. Vázquez, Spencer D. Proctor.  Novel chP3R99 mAb reduces subendothelial retention of atherogenic lipoproteins in Insulin-Resistant rats: Acute treatment versus long-term protection as an idiotypic vaccine for atherosclerosis. bioRxiv.  2023. DOI: 10.1101/2023.08.30.555546
  3. Frégeau G, Sarduy R, Elimam H, Esposito CL, Mellal K, Ménard L, Leitão da Graça SD, Proulx C, Zhang J, Febbraio M, Soto Y, Lubell WD, Ong H, Marleau S.  Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice.  Atherosclerosis.  2020  Aug;307:52-62.  PMID: 32721647.
  4. Soto Y, Mangat R, Kelly S, Vazquez AM, Proctor SD.  Anti-Glycosaminoglycan Monoclonal Antibody Prevents Cardiac Hypertrophy in a Rat Model of Metabolic Syndrome.  Atherosclerosis.  2019 Aug;287:E75.  DOI:  10.1016/j.atherosclerosis.2019.06.213.
  5. Soto Y, Mangat R, Kelly S, Vazquez AM, Proctor SD.  Novel Anti-proteoglycan Antibody Inhibits Arterial Lipoprotein Retention and Prevents Cardiac Hyperthrophy in a Rat Model of Insulin Resistance.  Atherosclerosis Supplements.  2018 June;32:27.   DOI:  10.1016/j.atherosclerosissup.2018.04.078.
  6. Brito V, Mellal K, Zoccal KF, Soto Y, Menard L, Sarduy R, Faccioli LH, Ong H, Vázquez AM, Marleau S.  Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice.  Frontiers in Pharmacology.  2017 Nov.  DOI:  10.3389/fphar.2017.00782.
  7. Sarduy R, Brito V, Castillo A, Soto Y, Griñán T, Marleau S, Vázquez AM.   Dose-Dependent Induction of an Idiotypic Cascade by Anti-Glycosaminoglycan Monoclonal Antibody in apoE -/- Mice: Association with Atheroprotection.  Front Immunol.  2017 Mar 3;8:232.  PMID  28316603.
  8. Mangat R, Soto Y, Vázquez AM, Proctor SD.  A Novel Anti-Proteoglycan Antibody Inhibits Arterial Retention of Remnant Lipoproteins in a Rat Model of Insulin Resistance.   The Canadian Journal of Cardiology.  2016 Oct;32(10):578.  DOI:  10.1016/j.cjca.2016.07.101.
  9. Delgado-Roche L, Brito V, Acosta E, Pérez A, Fernández JR, Hernández-Matos Y, Griñán T, Soto Y, León OS, Marleau S, Vázquez AM.  Arresting progressive atherosclerosis by immunization with an anti-glycosaminoglycan monoclonal antibody in apolipoprotein E-deficient mice.  Free Radic Biol Med. 2015 Dec;89:557-66.  PMID:  26454078. 
  10. Soto Y, Mesa N, Alfonso Y, Pérez A, Batlle F, Griñán T, Pino A, Viera J, Frómeta M, Brito V, Olivera A, Zayas F, Vázquez AM.  Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody.  MAbs.  2014 6(5):1340-6.  PMID:  25517318.
  11. Brito V, Mellal K, Zoccal KF, Soto Y, Ménard L, Sarduy R, Faccioli LH, Ong H, Vázquez AM, Marleau S.  Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice.  Front Pharmacol.  2017 Nov 1;8:782.   PMID:  29163168.  

Conference Presentations:

  1. Gala Araujo, Yosdel Soto, Rabban Mangat, Leidy Valencia, Agata Martin-Ozimek, Spencer Proctor.  Efficacy of novel production variants an chimeric anti-atherosclerotic antibody, CHP3R99, to produce an immune response.  Oral presentation.  Cardiovascular Research Institute (CVRI) Research Day 2023, University of Alberta, Edmonton, Alberta, Canada.
  2. Gala Araujo, Agata Martin-Ozimek, Leidy Valencia, Yosdel Soto, Spencer Proctor.  Immunogenicity of novel variants of the chimeric chP3R99 antiatherogenic antibody in insulin-resistant rats.   Poster presentation.   Alberta Diabetes Institute (ADI) Research Day 2023,  University of Alberta, Edmonton, Alberta, Canada.
  3. Gala Araujo, Agata Martin-Ozimek, Leidy Valencia, Yosdel Soto, Spencer Proctor.  Immunogenicity of novel variants of the chimeric chP3R99 antiatherogenic antibody in insulin-resistant rats and swine.  Canadian Lipid & Vascular Summit 2023, Prince Edward County, Ontario, Canada.